This article is more than 5 years old. Information may no longer be current.
VIDEO: IBD Expert Discusses Issues Surrounding Biosimilar Therapies
ORLANDO — David T. Rubin, MD, AGAF, FACG, professor of medicine and chief of the section of gastroenterology, hepatology and nutrition at University of Chicago Medicine, discusses his lecture aimed at introducing the concept of biosimilars to the audience at AIBD.
“Because biological therapies are so complex in their biological and protein structures, the concept of biosimilar implies that they have similar efficacy and safety, and are otherwise thought to be unique in the way they are made, but similar in the way they end up — and that’s a very important distinction,” Rubin said. “Biosimilars are in development across the world, and there are currently biosimilars for IBD that have already received regulatory approval, and are available in different countries in Europe, in Asia and elsewhere.”
Disclosures: Rubin reports financial relationships with AbbVie, Amgen, ACG, Cornerstones Health, Emmi, Genentech, Janssen, Pfizer, Prometheus Laboratories, Shire, Takeda and UCB.